Table 2.
Current studies of targeting on androgen/ androgen receptor in ovarian cancer cells.
| Study | Cell Lines | Treatment | MOA | Key Findings |
|---|---|---|---|---|
| Park et al. (2016) | OVCAR-3 | Enzalutamide | NR | Showed efficacy in the ovarian cancer with AR expression. |
| Lin et al. (2018) | A2780 and SKOV3 | ASC-J9 | Suppressing AR→Nanog axis |
AR promotes Nanog expression which contribute to CSPCs stemness in EOC cells |
| Chung et al. (2019) | HeyA8, SKOV3ip1, OVCAR-3 | Paclitaxel/ASC-J9 | Suppressing AR→ABCG2 axis | Degradation of AR is effective in suppressing OCSO subtype. |
| Addie et al. (2019) | A2780, OV90, OVCAR3, OVCAR8, SKOV3, COV362.4 | Metformin/enzalutamide | AR→PI3K pathway | Anti-androgen failed to suppress AR+ EOC cells, implicating an ligand-independent pathway of AR. |
Abbreviations: NR: not reported; AR: androgen receptor; CSPCs: cancer stem/progenitor cells; EOC: epithelial ovarian cancer; OCSC: ovarian cancer serous carcinoma; MOA: mode of action.